$193.72▾ 3.08%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
Not enough data yet
Valuation
96th pctvs its own history
Rich
Its valuation sits in the richer end of its own recent range.
Revenue growth
+9.4%year over year
Healthy
Revenue is growing at a steady pace.
Leverage
Not enough data yet
Term-debt data is not available for this company.
More coming: dilution / share-count creep.
Fair value
Overvalued
Trading about 8% above our fair-value range
A cash-flow (DCF) estimate cross-checked against peer multiples.
✦ The read
Illumina, Inc.'s earnings-quality signal is not available yet. Revenue is growing at a steady pace. Its valuation sits in the richer end of its own recent range.
Key numbers
Valuation
EPS (TTM)$5.36
TTM (trailing 12 months, through fiscal Q2 FY2027)
Profitability
Net margin18.4%
TTM (trailing 12 months, through fiscal Q2 FY2027)
Size
Revenue (TTM)$4.49B
TTM (trailing 12 months, through fiscal Q2 FY2027)
Recent news
Sentiment · last 30 days5 articles
3 bullish2 neutral0 bearish
AI Disruption Reshapes Bioinformatics: Record Investment and Breakthrough Tools Signal a New Era for Drug Discovery and Precision Medicine
Is Grail (GRAL) Stock a Buy, Sell, or Hold at Under $70?Blood Transfusion Diagnostics Market Size to Hit USD 8.67 Billion by 2035 as Automated Testing and AI-Driven Blood Safety Solutions Accelerate Growth | SNS Insider
Cancer Biomarkers Market to Reach US$ 54.48 Billion by 2032 as Precision Oncology and Multi-Omics Adoption Accelerate
Bioinformatics Collaboration and Licensing Deals 2019-2026 | Compare Upfronts, Milestones, and Royalties for 1,230+ Deals
Signals and key numbers are from the fiscal Q2 FY2027 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.